
Liquidity, historical trends, and peer comparisons.
According to uniQure N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 11.52. This represents a change of 8.76% compared to the average of 10.59 of the last 4 quarters.
The mean historical Current Ratio of uniQure N.V. over the last ten years is 10.06. The current 11.52 Current Ratio has changed 14.43% with respect to the historical average. Over the past ten years (40 quarters), QURE's Current Ratio was at its highest in in the December 2021 quarter at 17.09. The Current Ratio was at its lowest in in the September 2017 quarter at 3.64.
Average
10.06
Median
9.61
Minimum
6.28
Maximum
17.09
Discovering the peaks and valleys of uniQure N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 80.41%
Maximum Annual Current Ratio = 17.09
Minimum Annual Increase = -63.25%
Minimum Annual Current Ratio = 6.28
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 10.43 | 6.99% |
| 2024 | 9.74 | 10.13% |
| 2023 | 8.85 | 40.89% |
| 2022 | 6.28 | -63.25% |
| 2021 | 17.09 | 80.41% |
| 2020 | 9.47 | -22.02% |
| 2019 | 12.15 | 2.53% |
| 2018 | 11.85 | 40.40% |
| 2017 | 8.44 | 33.19% |
| 2016 | 6.34 | -26.28% |
The current Current Ratio of uniQure N.V. (QURE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
9.67
5-year avg
10.48
10-year avg
10.06
uniQure N.V.’s Current Ratio is greater than MeiraGTx Holdings plc (3.76), greater than Ultragenyx Pharmaceutical Inc. (1.40), greater than Neurogene Inc. (10.64), greater than REGENXBIO Inc. (2.86), greater than Voyager Therapeutics, Inc. (7.51), greater than Rocket Pharmaceuticals, Inc. (9.24), greater than 4D Molecular Therapeutics, Inc. (8.03),
| Company | Current Ratio | Market cap |
|---|---|---|
| 3.76 | $904.73M | |
| 1.40 | $1.69B | |
| 10.64 | $435.83M | |
| 2.86 | $508.96M | |
| 7.51 | $115.23M | |
| 9.24 | $286.51M | |
| 8.03 | $678.40M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like uniQure N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like uniQure N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is uniQure N.V.'s Current Ratio?
How is the Current Ratio calculated for uniQure N.V. (QURE)?
What is the highest Current Ratio for uniQure N.V. (QURE)?
What is the 3-year average Current Ratio for uniQure N.V. (QURE)?
What is the 5-year average Current Ratio for uniQure N.V. (QURE)?
How does the current Current Ratio for uniQure N.V. (QURE) compare to its historical average?